摘要
1例93岁男性患者因帕金森病、老年痴呆症服用多巴丝肼375 mg/d、盐酸苯海索2 mg/d、盐酸多奈哌齐5 mg/d、奥氮平2.5~5.0 mg/d.期间患者出现双下肢无力,服用奥氮平2年半后,实验室检查：LDH 351 U/L、CK 1425 U/L、Scr 259 μmol/L,不排除奥氮平致横纹肌溶解症.停用奥氮平,予以维生素B650 mg加入0.9%氯化钠注射液500 ml静脉滴注,1次/d;碳酸氢钠0.5 g口服,3次/d.第8天复查,LDH 326 U/L、CK 355 U/L、Scr 63 μmol/L.
A 93-year-old patient with Parkinson＇s disease and Alzheimer disease received oral levodopa and benserazide hydrochlo-ride 375 mg/d,benzhexol hydrochloride 2 mg/d,donepezil hydro-chloride 5 mg/d,olanzapine 2.5-5.0 mg/d. The patient occasionally felt lower extremities weakness during the medication period. After having olanzapine two and a half years,laboratory examination showed the following levels：lactate dehydrogenase 351 U/L,creatine kinase 1 425 U/L,serum creatine 259 μmol/L. Rhabdomyolysis induced by olanzapine could not be excluded. Olanzapine was stopped. The treatments with an IV infusion of vitamin B650 mg dissolved in 0.9% sodium chloride injection 500 ml once daily and oral sodium bicarbonate 0.5 g thrice daily were given. On day 8,the patient′s lactate dehydrogenase level was 326 U/L,creatine kinase level was 355 U/L,serum creatine level was 63 μmol/L.
出处
《药物不良反应杂志》
CSCD
2017年第5期390-392,共3页
Adverse Drug Reactions Journal
